Pulmonary Surfactant Proteins are Inhibited by IgA Autoantibodies in Severe COVID-19.
Tobias SinnbergChrista LichtensteigerOmar Hasan AliOltin T PopAnn-Kristin JochumLorenz RischSilvio D BruggerAna VelicDavid BomzePhilipp KohlerPietro VernazzaWerner C AlbrichChristian R KahlertMaire-Therese AbdouNina WyssKathrin HofmeisterHeike NiessnerCarl ZinnerMara GilardiAlexandar TzankovMartin RöckenAlex DulovicSrikanth Mairpady ShambatNatalia RuetaloPhilipp K BuehlerThomas C ScheierWolfram JochumLukas KernSamuel HenzTino SchneiderGabriela M KusterMaurin LampartMartin SiegemundRoland BingisserMichael SchindlerNicole Schneiderhan-MarraHubert KalbacherKathy D McCoyWerner SpenglerMartin H BrutscheBoris MacekRaphael TwerenboldJosef M PenningerMatthias S MatterLukas FlatzPublished in: American journal of respiratory and critical care medicine (2022)
Our data suggest that patients with severe COVID-19 harbor IgA against pulmonary surfactant proteins B and C and that these antibodies block the function of lung surfactant, potentially contributing to alveolar collapse and poor oxygenation. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).